Biosimilar Launch Notification Delay Remains, Might Not Matter For Newer Products
This article was originally published in The Pink Sheet Daily
Executive Summary
In Amgen v Apotex, Federal Circuit says biosimilar applicants still need to wait for FDA approval to give reference product manufacturer launch notification regardless of patent dance status, but court suggests notice could be given upon tentative approval.